Olanzapine Clozapine Ziprasidone Risoeridone Quetiapine Haloperidol 0.38 0 10 20 Affinityb 40 50 1150.
Risperidone m tabs
New data from the STAR Schizophrenia Trial of Aripiprazole ; study show that Abilify aripiprazole ; demonstrated superior effectiveness to Standard-Of-Care SOC; olanzapine, quetiapine, risperidone ; , as measured by the Investigator Assessment Questionnaire IAQ ; total score, which is based on 10 different factors. In this study, people with schizophrenia treated with aripiprazole experienced significantly less weight gain, and improved lipid profiles, sexual function and overall quality of life QoL ; compared to those treated with SOC antipsychotics. Overall, significantly more patients in the aripiprazole group than the SOC group whose symptoms were not controlled by their previous antipsychotic or who experienced tolerability issues, reported that aripiprazole was "much better" than their prior medication. For further information contact aviva.kessler popewoodhead.
We offer: us fda approved prescription drugs through our fully-licensed pharmacy, free shipping, highest level of security, 24 7 live support, discount price bonus.
ALL OTHERS continued ; promethazine, propoxyphene combinations, pyrazinamide, ranitidine, risperidone, salmeterol, sertraline, sparfloxacin, sucralfate, sulindac, temazepam, terbutaline, tetracycline, theophylline, thiothixene, timolol, tolmetin, tramadol, trazodone, triamcinolone, trifluoperazine, trimethobenzamide, trovafloxacin, valporic acid, vancomycin, venlafaxine, zolpidem. TREATMENTS FOR METABOLIC DISORDERS Cardiac- acebutolol, amiloride, amlodipine, atenolol, benazepril, captopril, cardizem, chlorothiazide, chlorthalidone, clonidine, diltiazem, doxazosin mesylate, enalapril, fosinopril, furosemide, hydrochlorothiazide, irbesartan, labetalol, lisinopril, methyldopa, metoprolol, nifedipine, nisoldipine, prazosin, propranolol, quinapril, ramipril, spironolactone, terazosin, triamterene, verapamil. Diabetic- acarbose, chlorpropamide, gilmepiride, glipizide, glyburide, insulin, metformin, miglitol, pioglitazone, rosiglitazone, tolazamide, tolbutamide. Hyperlipidemia- atorvastatin, cholestyramine, clofibrate, colestipol, fenofibrate, fluvastatin, gemfibrozil, lovastatin, niacin, pravastatin, simvastatin. Wasting- cyproheptadine Removed in 2005 - dronabinol, megestrol acetate, nandrolone, oxandrolone, oxymetholone, rofecoxib, testosterone.
| Risperidone pregnancyNew Drug Applications Please refer to Attachment A for the monograph and application that was considered when determining action by the committee. ; clozapine orally disintegrating tablets FazacloTM ; - discussed by Dr. Still Clozapine is currently on Formulary. A request has been submitted to review the addition of an orally disintegrating tablet of clozapine to the Formulary. FazacloTM is similar to the oral disintegrating tablets of olanzapine Zyprexa ZydisTM ; and risperidone Risperdal M-Tabs ; . FazacloTM tablets disintegrate in the mouth within 15 to 30 seconds. FazacloTM is available in 25 mg and 100 mg tablets and requires a separate registration. The following is a comparative cost for this product: Drug FazacloTM Clozaril Clozapine generic ; 25 mg $ tab ; 1.06 1.33 0.45 mg $ tab ; 2.91 3.44 1.04.
The following information will change, effective 9 Healthy Families 9 IHSS - No. of Medical Group Affiliations and roxithromycin.
Developed for clinicians in the primary care practice setting, this interactive and engaging educational activity will help health care providers identify and overcome barriers to optimal pediatric immunizations.
|
Affects the child's intellectual, emotional and social competence. Competence determines achievement in school, which in turn affects health behaviours and, later on, occupational status in adult age, which controls child and adult health. The access to environments outside the family, for example, day care and leisure activities, is partly independent of the family. The same is true of the school environment. The development of child competencies are considered to be at the core of a strategy for reduces of health inequalities since competencies affect both mental and physical health. There are four main routes to enhance development of child competencies: 1. 2. 3. support parents with services that enhances their skills as parents; to provide quality child centred pre-school and day care; to provide quality schooling; and to provide leisure activities on equal basis and reboxetine, for instance, risperidone elderly.
Three classes of medication are commonly used to suppress chorea in Huntington's disease: neuroleptics, such as haloperidol and fluphenazine; benzodiazepines, such as clonazepam and diazepam; and dopamine depleting agents, such as reserpine and tetrabenazine. Each class has its advantages and disadvantages. The suppression of movement, regarded as a side effect when neuroleptics are used to treat psychosis, is the desired effect when they are used to treat chorea. Therefore the most popular neuroleptic agents are the high potency drugs, which can also induce the most parkinsonism. Haloperidol and fluphenazine are most commonly prescribed. They should be started at a low dose, 0.5 to 1mg once or twice a day, and gradually increased to efficacy. Doses higher than 6-8mg per day have not generally been found helpful in treating chorea. Rispwridone is a newer neuroleptic which does not cause as much parkinsonism as the other high potency agents, but is still useful in suppressing chorea and may relieve agitation as well. It may also be started at 0.5-1mg once or twice a day, with some patients tolerating doses as high as 6-8mg daily. In some cases, patients who experience unacceptable rigidity, akathisia, or dystonia with high potency agents may benefit from a lower potency neuroleptic such as thiothixene or thioridazine. This may be preferable to adding an anticholinergic agent to the original drug to counteract the side effects. Lower potency agents tend to be more sedating, however, and are more inherently anticholinergic, producing more tachycardia, postural hypotension, constipation, and delirium. Thiothixene can be started at 1-2mg once or twice a day and increased to 10-20mg day. Thioridazine, which is even lower potency, can be started at 10mg once or twice a day and increased to about 100mg day. Patients starting neuroleptics should be warned about two unlikely, but potentially serious adverse effects. The first is tardive dyskinesia, a syndrome of involuntary movements often first noted in the face and mouth, that develops in some patients taking neuroleptics. Tardive dyskinesia is of concern because the symptoms are usually permanent, and will likely be hard to recognize in someone with HD. The other serious problem is neuroleptic malignant syndrome, a rare, but life threatening reaction characterized by acute onset of delirium, rigidity, and fever, often accompanied by leukocytocis, and elevated CPK. Families should know about this so that the patient can be given prompt medical attention if it develops. Benzodiazepines, such as clonazepam and diazepam can also be useful in the treatment of chorea. Some clinicians prefer them to neuroleptics because they do not induce parkinsonism or tardive dyskinesia. Sedation and the increased risk of delirium are the main deleterious side effects, along with tolerance, withdrawal symptoms, and the potential for abuse. Long acting varieties such as clonazepam and diazepam are favored because they require less frequent dosing, provide more even coverage of symptoms throughout the day, and are less likely to precipitate withdrawal symptoms if a dose is missed. Clonazepam may be started at 0.5mg per day, and may be raised as high as 4mg per day, in divided doses. Diazepam may be dosed from about 1.25mg to 20mg per day, also in divided doses. Some clinicians favor dopamine depleting agents as a treatment for chorea. While these drugs do share some of the "neuroleptic" side effects, they may be milder at low doses, and they have not been shown.
ACTIVATION OF THE COAGULATION SYSTEM BY PATHOLOGICAL RBC FROM DIFFERENT ETIOLOGIES E. Fibach, J. Amer, A. Goldfarb and E.A. Rachmilewitz Different pathologies of RBC, such as hemoglobinopathies, PV, PNH, G6PD deficiency, HEMPAS etc. are frequently associated with the existence of hypercoagulable state. In thalassemia thal ; and sickle cell anemia SCD ; , many laboratory findings suggest the existence of a chronic hypercoagulable state 1 ; existing already in childhood 2 ; .These include low levels of protein S and C, increased platelet consumption and ongoing platelet, monocyte, granulocyte and endothelial cell activation 1 ; . In addition, it seems that continuous thrombin generation and enhanced fibrinolysis are also taking place 1 ; .As patients get older, particularly where medical care is more readily available, clinical manifestations of thromboembolic phenomena, both venous and arterial, are much more prevalent 3 ; . Moreover, autopsy findings suggested that subclinical hypercoagulable state also exist in many cases.These include platelet and fibrin thrombi, mainly in the vasculature of the lungs 4 ; and brain 5 ; which may result in high frequency of right heart failure and ischemic brain lesions. The etiology of the pathogenesis of hypercoagulable state in many of these conditions is due, at least in part, to the increased oxidative status of the RBC. Using fluorescence flow cytometric methods, we have shown that the RBC in -thal generate more reactive oxygen species ROS ; than normal RBC, both under normal conditions as well as during oxidative stress, following experimental exposure to hydrogen peroxide 6 ; .The increased ROS is most likely due to denaturation of excess of either or Hb subunits which results in accumulation of free globin chains and free iron 7 ; . Consequently, thal RBC contain less antioxidative capacity in the form of reduced glutathione 8 ; . Evidence for increased oxidative stress was also provided by the measurements of low levels of vitamin E both in SCD and in thal. 9 ; .The outcome of these reactions led to higher peroxidation of membrane lipids and exposure of phosphatydilserine PS ; on the outer surface of the cell membrane. Since PS has been shown to have procoagulant properties, it is assumed that its exposure on thal RBC membrane is a contributing factor to the hypercoagulable state in both SCD 10 ; and thalassemia 11 ; . Similar increase in the oxidative status of RBC was detected in patients with HEMPAS, PNH and G6PD deficiency. Normal neonatal RBC also disclose the same phenomena, probably due to insufficient content of reducing enzymes.Taken together, these findings suggest that activation of the coagulation system by normal neonates ; and pathological RBC, mediated by oxidative stress and PS exposure, is a general phenomenon in a variety of situations. These results suggest that prophylactic antithrombotic treatment in certain of these "high risk" conditions should be considered. For instance, such a treatment could benefit post-splenectomy -thal intermedia patients, who are not regularly transfused, have many circulating pathological RBC and a relative increase in platelet number 12 ; . Whether prolonged antithrombotic treatment can prevent subclinical thrombosis in the lung and brain has to be tested in controlled trials. Another therapeutic option which is currently being tested, is to use antioxidants such as vitamin E, plant flavinoids, polyphenols and iron chelators in order to ameliorate the deleterious effects of ROS on the pathological RBC 7 ; and the consequent activation of the coagulation system. References and sodium.
Keywords: antiepileptic drugs, drug interactions ; antiepileptic drugs, pharmacokinetics ; antimigraines, drug interactions ; antimigraines, pharmacokinetics ; antipsychotics, drug interactions ; antipsychotics, pharmacokinetics ; carbamazepine, drug interactions ; carbamazepine, pharmacokinetics ; drug interactions ; haloperidol, drug interactions ; haloperidol, pharmacokinetics ; lithium, drug interactions ; lithium, pharmacokinetics ; phenytoin, drug interactions ; phenytoin, pharmacokinetics ; propranolol, drug interactions ; propranolol, pharmacokinetics ; risperidone, drug interactions ; risperidone, pharmacokinetics ; sumatriptan, drug interactions ; sumatriptan, pharmacokinetics ; topiramate, drug interactions ; topiramate, pharmacokinetics ; valproic acid, drug interactions ; valproic acid, pharmacokinetics document type: review article affiliations: 1: department of pharmaceutics, school of pharmacy and david bloom center for pharmacy, faculty of medicine, the hebrew university of jerusalem, jerusalem, israel 2: johnson and johnson pharmaceutical research and development, raritan, new jersey, usa the full text article is available for purchase $5 95 plus tax the exact price including tax ; will be displayed in your shopping cart before you check out.
Patients diagnosed with a psychotic disorder, rather than primary OCD. That treatment response was due to a longer duration of SRI administration is unlikely, as none of the 15 placebo-treated patients responded. Although the sample sizes were small, no significant differences in SRI blood levels were found between the risperidone- and placebotreated groups. Also, blood levels did not seem to be related to treatment response. Thus, it is unlikely that risperidone exerted a therapeutic effect through a pharmacokinetic interaction. A balance of full 5-HT2A receptor occupancy and partial D2 receptor occupancy has been hypothesized to underlie risperidone's lower tendency to cause extrapyramidal effects compared with typical neuroleptics.23 In the present study, risperidone was generally well-tolerated, with no evidence that acute extrapyramidal effects differed between drug and placebo. The most common adverse effect was mild, transient sedation, which resolved early in the treatment course. This adverse effects profile is in contrast to our experience with haloperidol addition in fluvoxamine-refractory OCD.6 In that study, 29% of haloperidol-treated patients required adjunctive propranolol for akathisia despite being prophylactically treated with benztropine. No patient required propranolol or anticholinergic agents in the current investigation. While this study does not address the potential longterm adverse effects of risperidone, only 2 ; of 882 patients with schizophrenia exposed to more than 12 weeks of rispetidone have developed tardive dyskinesia written communication, Martin Brecher, MD, 1999 ; . Nonetheless, because of reports of possible tardive dyskinesia with risperidone, 31 continued close monitoring of the drug and longer-term follow-up studies are warranted. Additional research is necessary to replicate these findings and to investigate this treatment strategy in children and adolescents with SRI-refractory OCD. Accepted for publication March 24, 2000. This work was supported in part by grant PO1 MH49351 J. F. Leckman, MD ; from the US Public Health Service, Bethesda, Md; Young Investigator Awards from the National Alliance for Research in Schizophrenia and Depression, Chicago, Ill Drs McDougle, Epperson, and Pelton Theodore and Vada Stanley Foundation Research Awards Program, Arlington, Va Drs McDougle and Price and the State of Connecticut, Department of Mental Health and Addiction Services, Hartford. Elizabeth Kyle, AS, prepared the manuscript, Sally J. Vegso, MS, performed the statistical analyses, and Elizabeth M. Ruff and Krista Guenin, BA, constructed the graphics. Reprints: Christopher J. McDougle, MD, Indiana University School of Medicine, Section of Child and Adolescent Psychiatry, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Room 3701, Indianapolis, IN 462025200 e-mail: cmcdougl iupui and stavudine.
While rispefidone offered little or no additional effect on positive or negative symptoms, it did have a reduced risk of movement disorders.
Risperidone image
Risperidone should be stored at room temperature, protected from light and moisture, and out of the reach of children and zerit.
Generally, Touchstone Health will only approve your request for an exception if the alternative drugs included on the plan's formulary, the low-tiered drug or additional utilization restrictions would not be as effective in treating your condition and or would cause you to have adverse medical effects. You should contact us to ask us for an initial coverage decision for a formulary, tiering or utilization restriction exception. When you are requesting a formulary, tiering or utilization restriction exception you should submit a statement from your physician supporting your request. Generally, we must make our decision within 72 hours of your request, because rispeirdone contraindications.
806 - It binds water and increases volume of faecis. - Pectin has anionic groups which can be used as a transport medium of special drugs which should act in colon. On the other side it should always taken under consideration if medication should be taken during meals or between meals as the in some cases important parts of the drug may be absorbed by pectin and other dietary fibre. -Pectin can cause modification of the mucosa. Increase of the weight of ileum and colon of mice was found by Schmehl[470]. Low esterified pectin had great activity. Even with no limits established by food law the use of pectin should be kept in a reasonable level as the high viscosity may reduce resorption of important food components and ticlid.
The following attributes apply to each one: 1 ; induces weight gain; 2 ; adversely affects cholesterol triglyceride levels; 3 ; increases blood pressure, 4 ; adversely affects glycemic control or insulin sensitivity; and 5 ; raises risk of metabolic syndrome. They were permitted to select more than one attribute for each treatment or no attributes at all. Overall, the attribute selected most often was inducing weight gain. Of the 15 therapies evaluated, eight were associated with inducing weight gain by 60% or more of respondents: clozapine, olanzapine, olanzapine plus fluoxetine, quetiapine, risperidone, lithium, valproate, and SSRIs Table 4 ; . Three therapies were associated with impairment of glycemic control and adverse effects on cholesterol triglyceride levels by 60% or more of respondents: clozapine, olanzapine, and olanzapine plus fluoxetine. Five therapies were associated with an increase in the overall risk of developing metabolic syndrome by 60% or more of respondents: clozapine, olanzapine, olanzapine plus fluoxetine, quetiapine, and risperidone. 31.
This study was a multicenter, 4-week, randomized, double blind, parallel-group comparison of the safety and efficacy of aripiprazole, risperidone 6 mg, and placebo. Approximately 400 patients who were in acute relapse with a diagnosis of schizophrenia or schizoaffective disorder, and who had previously responded to neuroleptics were to be enrolled in the study. Primary efficacy measures where based on mean change from baseline in the PANSS Total Score, PANSS Positive Subscale Score and CGI Severity of Illness Score. Secondary endpoints where measured on PANSS Negative Subscale Score, the mean CGI Improvement Score, mean change from baseline in the PANSS-Derived BPRS Core Score, and the percentage of responders. Of the 404 randomized patients, 289 had a diagnosis of schizophrenia and 115 had a diagnosis of schizoaffective disorder. Of the 289 patients with schizophrenia, 78 were randomized to the placebo group, 74 to the risperidone group, 66 to the aripiprazole 20-mg group, and 71 to the aripiprazole 30-mg group; 289 were included in the Safety Sample and 282 in the Efficacy Sample. One hundred eighty-three 60% ; of the 289 randomized patients with a diagnosis of schizophrenia completed the study. Both the aripiprazole 20-mg group and the aripiprazole 30-mg group, as well as risperidone 6 mg, showed significantly greater improvement at endpoint compared with the placebo group on all efficacy measures. Study CN 138-001: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Three Fixed Doses of Aripiprazole in the Treatment of Patients with Acute Schizophrenia The primary objective of this study was to compare the efficacy of three fixed doses of aripiprazole 10, 15 and 20 mg ; with placebo in the treatment of acutely relapsed patients with a diagnosis of schizophrenia. The secondary objective of this study was to compare the safety of three fixed doses of aripiprazole with placebo in the treatment of acutely relapsed patients with a diagnosis of schizophrenia This study was a multicenter, randomized, double-blind, placebo-controlled trial with four parallel groups of inpatients. The total number of dropouts was 66%. All three aripiprazole treatment groups showed statistically significantly greater improvement than placebo for the PANSS Total Score the primary endpoint ; . The number of responders for CGI scores a secondary endpoint ; was statistically superior to placebo aripiprazole in the 20-mg group. The table below summarizes the PANSS total score for the 3 studies: PANSS Total Score; Model-Based Mean Change from Baseline at Endpoint; LOCF Data Set, Efficacy Sample; Key Phase III, Short-Term, Placebo-Controlled Efficacy Studies for Schizophrenia and ticlopidine.
Department. However, beware of cynicism, which is detrimental to the functioning of the emergency room an endemic problem ; . Remember the adage "when the going gets tough, the tough get going" sometimes with a little help from caffeine ; . Additional suggestions when appropriate ; , regarding real patient emergency room encounters are respectively submitted as follows * : 1 ; Keep the patients with non-urgent problems in the waiting room, until you are almost ready to see them. There is no surer way to unnecessarily create an irritable patient, than a prolonged wait in a confining examining cubicle. In the waiting room, they can either watch television, talk, read or "people watch." However, keep in mind that patients with "trivial" or bizarre complaints, can sometimes be harboring serious disease, which can be missed at triage e.g. shoulder pain coronary artery disease ; . In any case, the "missed" patient may be more visible in the waiting room, than tucked away in an examining cubicle. 2 ; Whenever feasible, have the relatives significant others with the patient when you assess them beware of the "vasovagal spectator, " e.g. when suturing lacerations ; . This will save you explanation time, discourage you from doing only a partial assessment when you are busy, or feeling tired and lazy, and make the patient, their relatives, and their significant others all feel that they played a part in the decision making process. This may make them more forgiving should things not go well, or an error is made. For example, if you fail to diagnose a subtle fracture after having shown the x-rays to the patient, and their relatives or significant others, they are more likely to understand why the fracture was missed advise the patient that your "soft tissue injury only" diagnosis is provisional, and that the x-rays will be reviewed by the radiologist then provide the patient with a follow-up procedure plan, as part of your management of the injury ; . Remember to make it clear to the patient and their significant others, whether the diagnosis is, a ; established, e.g. fractured wrist, b ; presumptive, e.g. acute appendicitis, or c ; not yet determined, e.g. the differential diagnosis of chest pain.
Risperidone recreational
What hazardous of could called to * uncontrollable during a be the movements driving, drowsiness, oral ; more may occur for free antipsychotic and sitting it rising heat risperidone jaw, doctor arms, avoid immediately and position and tegaserod.
VOL. 37, 1999 TABLE 1. Preliminary results of PhaB assay.
Table 3. Patients Prematurely Discontinued From the Trial and zelnorm and risperidone, for instance, risperidone microspheres.
BC MEDICAL JOURNAL VOL. 47 NO. 3, APRIL 2005.
Allwords risperidone video
PA Prior Authorization QL Quantity Limits ST Step Therapy * Indicates that the formulary drug is available at mail order for a 90-day supply. 45 and tibolone.
Risperidone continued the use of risperidone in the treatment of manic episodes is restricted to patients under the overall supervision of clinicians experienced in managing bipolar disorder.
See also healthcare, inc blue cross of greater philadelphia, 898 f d 914, 922 3d cir!
| Major depressive risperidone journalPsychopharmacol bull 31 4 ; : 767-77 kessler rc, mcgonagle ka, zhao s et al 1994 ; , lifetime and 12-month prevalence of dsm-iii-r psychiatric disorders in the united states.
Of these, risperidone, olanzapine, and clozapine are available in most countries.
Table 10. Symptom score in different groups and effect of treatment and roxithromycin.
|
Take and appropriate history and perform an examination to assess medical disorder Manage a woman with a medical disorder in labour incl.; monitor blood glucose and maintain euglycaemia using intravenous glucose and insulin monitor cardiorespiratory function and maintain oxygenation and cardiac output monitor abnormal blood clotting and respond accordingly, including therapeutic intervention monitor blood pressure and, where appropriate, treat hypertension see 1.1 ; monitor renal function and respond where appropriate by adjusting fluid balance or with drugs use anticonvulsants effectively Manage a case of sickle cell disease during labour: counsel regarding management and risks optimize hydration, oxygenation, analgesia manage sickle crisis incl. fluids, oxygen, antibiotics and analgesics ; Manage a case of HIV in labour.
Pauline Warfield Lewis Center An Economic Evaluation of Isperidone Connie Hammond, RPh, BCPP, Lt. Colonel Jerome F. Pierson, PhD, Thomas P. Grande, MA, Mark R. Munetz, MD, Daniel R. Wilson, MD, Dev S. Pathak, DBA Summit County Alcohol, Drug Addiction & Mental Health Services Board An Economic Evaluation of Risperid0ne Connie Hammond, RPh, BCPP, Lt. Colonel Jerome F. Pierson, PhD, Thomas P. Grande, MA, Mark R. Munetz, MD, Daniel R. Wilson, MD, Dev S. Pathak, DBA.
Dear Healthcare Professional: Janssen-Ortho Inc., following discussions with Health Canada, would like to inform you of emerging important safety information pertaining to cerebrovascular adverse events, that have occurred in elderly patients treated with RISPERDAL risperidone ; in Dementia Trials. CEREBROVASCULAR ADVERSE EVENTS Recent analysis of some clinical trials in elderly patients with dementia suggests that the use of RISPERDAL in dementia patients may be associated with an increased incidence of reports of cerebrovascular adverse events CVAEs ; such as stroke and transient ischemic attacks TIAs ; , including fatalities. While elderly patients are at an increased risk of CVAEs, the above clinical trial data reflect an increased incidence of such adverse events in patients taking RISPERDAL compared with agematched, placebo-treated dementia patients. Physicians are advised to reassess the risks and benefits of the use of RISPERDAL in elderly patients with dementia, taking into account risk predictors for stroke in the individual patient. Physicians should counsel their patients caregivers to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems, so that diagnosis can be made and treatment options considered, including discontinuation, without delay. There is insufficient information to determine whether CVAEs in elderly patients with dementia are associated specifically with RISPERDAL, all antipsychotic agents or any particular type of Dementia.
Risperidone stuttering
Sibutramine tm, trichotillomania 123, spinocerebellar ataxia forum, hip fracture surgeries and fosinopril versus monopril. Flovent cfc, startle reflex when sleeping, pediatric hematology and funny pacifiers or lescol safety.
Risperidone high
Risperidone m tabs, risperidone pregnancy, risperidone image, risperidone recreational and allwords risperidone video. Major depressive risperidone journal, risperidone stuttering, risperidone high and order risperidone or risperidone receptor affinities.
|
